A COMPREHENSIVE REVIEW ON PRONIOSOMES: A NEW CONCEPT IN OCULAR DRUG DELIVERY
DOI:
https://doi.org/10.22159/ijcpr.2023v15i5.3048Keywords:
Ocular drug delivery, Proniosome, Bioavailability, Biocompatible, Lipophilic, Pro-vesicleAbstract
The concept of novel drug delivery with the comparison of modern and conventional delivery system. The Ocular is the most challenging organ to deliver drugs after the brain and conventional delivery systems currently available in the arsenal have severe limitations thus there is a strong demand for an improved ocular delivery system and a suitable opinion is a novel drug delivery system. Noisome and liposome are dominant vesicular carriers in ocular drug delivery, as both systems improve the bioavailability of drugs and are well tolerated in ocular; however, both delivery systems have critical drawbacks of physicochemical stability during storage, lacking contain in dispersion and fusion of nanoparticles. The gel form is formulated by the coacervation phase’s parathion method. The material utilized for the formulation of proniosomes are non-ionic surfactant, cholesterol, carrier and alcohol are well tolerable and nontoxic in the ocular. The benefits offered to ocular drug delivery are prolonged retention time of formulation on the ocular surface, enhance ocular penetration to deliver effective therapeutic dosage, improve bioavailability of hydrophobic, lipophilic and herbal drugs, biocompatible, biodegradable, nontoxic and stable stored in pro-vesicle state. Hereby article will review proniosomes drug delivery from the perspective of ophthalmic delivery, discussing proniosomes as an ocular carrier, materials and methods their effect on ocular drug delivery and depth explanation of recent studies of proniosome in the ocular. Proniosomes are one of the sterile drug delivery systems that have seen a tremendous increase in popularity and are heavily utilized in cancer therapy. Researchers and academicians generally agree that incorporating the medicine into niosomes will improve its ability to target tissues where it is needed. Proniosomes created by academics and researchers. Niosomes that are produced from protostomes are a promising medication delivery system. They are well known for avoiding several issues related to aqueous noisome dispersion as well as issues with physical stability such aggregation, fusion, and leakage. They make transportation, distribution, storage, and dosage even more convenient. Proniosomes not only present a promising medication delivery method but also have the potential to speed up the skin barrier's repair.
Downloads
References
Gaudana R, Anathula HK, Parenky A, Mitra AK. Ocular drug delivery. American Association of Pharmaceutical Scientists. 2010 Sep;12(3):348-60.
Bachu RD, Chowdhury P, Al-Saedi ZHF, Karla PK, Boddu SHS. Ocular drug delivery barriers-role of nanocarriers in the treatment of anterior segment ocular diseases. Pharmaceutics. 2018 Feb 27;10(1):28. doi: 10.3390/pharmaceutics10010028, PMID 29495528.
Shell JW. Ophthalmic drug delivery systems. Surv Ophthalmol. 1984 Sep 1;29(2):117-28. doi: 10.1016/0039-6257(84)90168-1, PMID 6505951.
Yellepeddi VK, Palakurthi S. Recent advances in topical ocular drug delivery. J Ocul Pharmacol Ther. 2016 Mar 1;32(2):67-82. doi: 10.1089/jop.2015.0047, PMID 26666398.
Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World J Pharmacol. 2013;2(2):47-64. doi: 10.5497/wjp.v2.i2.47, PMID 25590022.
Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res. 2009 May;26(5):1197-216. doi: 10.1007/s11095-008-9694-0, PMID 18758924.
Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today. 2008 Feb 1;13(3-4):144-51. doi: 10.1016/j.drudis.2007.10.021, PMID 18275912.
Ahmad MZ, Mohammed AA, Mokhtar Ibrahim M. Technology overview and drug delivery application of proniosome. Pharm Dev Technol. 2017 Apr 3;22(3):302-11. doi: 10.3109/10837450.2015.1135344, PMID 26794727.
Bayindir ZS, Yuksel N. Provesicles as novel drug delivery systems. Curr Pharm Biotechnol. 2015;16(4):344-64. doi: 10.2174/1389201016666150206101443, PMID 25658383.
Bachhav AA. Proniosome: a novel nonionic provesicules as potential drug carrier. Asian J Pharm (AJP) Free Full Text Artic Asian J Pharm. 2016 Sep 10;10(03).
Hu C, Rhodes DG. Proniosomes: a novel drug carrier preparation. Int J Pharm. 1999 Aug 5;185(1):23-35. doi: 10.1016/s0378-5173(99)00122-2, PMID 10425362.
Hofland HEJ, Bouwstra JA, Ponec M, Bodde HE, Spies F, Verhoef JC. Interactions of non-ionic surfactant vesicles with cultured keratinocytes and human skin in vitro: a survey of toxicological aspects and ultrastructural changes in stratum corneum. J Control Release. 1991 Jun 1;16(1-2):155-67. doi: 10.1016/0168-3659(91)90039-G.
Sadiq M, Nirosha K. Review on proniosome-a novel approach to vesicular system. Int J Novel Trends Pharm Sci. 2014 Sep 10;4(5):97-100.
Li Q, Li Z, Zeng W, Ge S, Lu H, Wu C. Proniosome-derived niosomes for tacrolimus topical ocular delivery: in vitro cornea permeation, ocular irritation, and in vivo anti-allograft rejection. Eur J Pharm Sci. 2014 Oct 1;62:115-23. doi: 10.1016/j.ejps.2014.05.020, PMID 24905830.
Vora B, Khopade AJ, Jain NK. Proniosome based transdermal delivery of levonorgestrel for effective contraception. J Control Release. 1998 Jul 31;54(2):149-65. doi: 10.1016/s0168-3659(97)00100-4, PMID 9724902.
Khatoon M, Shah KU, Din FU, Shah SU, Rehman AU, Dilawar N. Proniosomes derived niosomes: recent advancements in drug delivery and targeting. Drug Deliv. 2017 Nov 1;24(2);Suppl1:56-69. doi: 10.1080/10717544.2017.1384520, PMID 29130758.
Proniosome UTA. A novel approach to vesicular drug delivery. Int J Pharm Pharm Sci Res. 2013;3(1):1-6.
Rajkumar J. Gv R, Burada S. Recent update on proniosomal gel as topical drug delivery system. Asian J Pharm Clin Res. 2019 Jan 7;12(1):54-61.
Gad HA, Kamel AO, Sammour OA, El Dessouky HF. Vesicular powder as carrier for doxycycline hydrochloride and metronidazole combination therapy. Pharm Dev Technol. 2014 Sep 1;19(6):755-68. doi: 10.3109/10837450.2013.829098, PMID 23981239.
Song S, Tian B, Chen F, Zhang W, Pan Y, Zhang Q. Potentials of proniosomes for improving the oral bioavailability of poorly water-soluble drugs. Drug Dev Ind Pharm. 2015 Jan 2;41(1):51-62. doi: 10.3109/03639045.2013.845841, PMID 24111828.
Yuksel N, Bayindir ZS, Aksakal E, Ozcelikay AT. In situ niosome forming maltodextrin proniosomes of candesartan cilexetil: in vitro and in vivo evaluations. Int J Biol Macromol. 2016 Jan 1;82:453-63. doi: 10.1016/j.ijbiomac.2015.10.019, PMID 26455402.
Shehata TM, Abdallah MH, Ibrahim MM. Proniosomal oral tablets for controlled delivery and enhanced pharmacokinetic properties of acemetacin. AAPS PharmSciTech. 2015 Apr;16(2):375-83. doi: 10.1208/s12249-014-0233-5, PMID 25319057.
Shukr MH, Eltablawy NA. Development and optimization of novel controlled-release pioglitazone provesicular powders using 3² factorial design. Drug Deliv Transl Res. 2015 Feb 1;5(1):51-62. doi: 10.1007/s13346-014-0215-x, PMID 25787339.
Viswanath V, Tulasi P. Formulation, optimization and characterization of betaxolol hydrochloride proniosomes using 3-2 factorial design. Int J Res Pharm Sci Tech. 2020 Feb 18;1(3):89-97. doi: 10.33974/ijrpst.v1i3.161.
Abd-Elbary A, El-Laithy HM, Tadros MI. Sucrose stearate-based proteosome-derived niosomes for the nebulisable delivery of cromolyn sodium. Int J Pharm. 2008 Jun 5;357(1-2):189-98. doi: 10.1016/j.ijpharm.2008.01.056, PMID 18339494.
Nasr M. In vitro and in vivo evaluation of proniosomes containing celecoxib for oral administration. AAPS PharmSciTech. 2010 Mar;11(1):85-9. doi: 10.1208/s12249-009-9364-5, PMID 20058106.
Marwa HA, Omaima AS, Hanaa AE, Hanan ME. Optimizing proniosomes for controlled release of ketoprofen using box-behnken experimental design. Int J Pharm Sci Res. 2011 Aug 1;2(8):2195.
Verma P, Prajapati SK, Yadav R, Senyschyn D, Shea PR, Trevaskis NL. Single intravenous dose of novel flurbiprofen-loaded proniosome formulations provides prolonged systemic exposure and anti-inflammatory effect. Mol Pharm. 2016 Nov 7;13(11):3688-99. doi: 10.1021/acs.molpharmaceut.6b00504, PMID 27632682.
Li Y, Dong C, Cun D, Liu J, Xiang R, Fang L. Lamellar liquid crystal improves the skin retention of 3-O-ethyl-ascorbic acid and potassium 4-methoxysalicylate in vitro and in vivo for topical preparation. AAPS PharmSciTech. 2016 Jun;17(3):767-77. doi: 10.1208/s12249-015-0353-6, PMID 26349686.
Bai Y, Abbott NL. Recent advances in colloidal and interfacial phenomena involving liquid crystals. Langmuir. 2011 May 17;27(10):5719-38. doi: 10.1021/la103301d, PMID 21090596.
Mehta M, Dureja H, Garg M. Development and optimization of boswellic acid-loaded proniosomal gel. Drug Deliv. 2016 Oct 12;23(8):3072-81. doi: 10.3109/10717544.2016.1149744, PMID 26953869.
Rajabalaya R, Leen G, Chellian J, Chakravarthi S, David SR. Tolterodine tartrate proniosomal gel transdermal delivery for overactive bladder. Pharmaceutics. 2016 Sep;8(3):27. doi: 10.3390/pharmaceutics8030027, PMID 27589789.
Abdelbary GA, Aburahma MH. Oro-dental mucoadhesive proniosomal gel formulation loaded with lornoxicam for management of dental pain. J Liposome Res. 2015 Apr 3;25(2):107-21. doi: 10.3109/08982104.2014.941861, PMID 25058447.
M Abdou E, M Ahmed N. Terconazole proniosomal gels: effect of different formulation factors, physicochemical and microbiological evaluation. J Pharm Drug Deliv Res 2016;5:1. doi: 10.4172/2325-9604.1000144.
Abdelbary GA, Amin MM, Zakaria MY. Ocular ketoconazole-loaded proniosomal gels: formulation, ex vivo corneal permeation and in vivo studies. Drug Deliv. 2017 Jan 1;24(1):309-19. doi: 10.1080/10717544.2016.1247928, PMID 28165809.
Khalil RM, Abdelbary GA, Basha M, Awad GE, El-Hashemy HA. Design and evaluation of proniosomes as a carrier for ocular delivery of lomefloxacin HCl. J Liposome Res. 2017 Apr 3;27(2):118-29. doi: 10.3109/08982104.2016.1167737, PMID 27079800.
Chen S, Hanning S, Falconer J, Locke M, Wen J. Recent advances in non-ionic surfactant vesicles (niosomes): fabrication, characterization, pharmaceutical and cosmetic applications. Eur J Pharm Biopharm. 2019 Nov 1;144:18-39. doi: 10.1016/j.ejpb.2019.08.015, PMID 31446046.
Sahoo RK, Biswas N, Guha A, Sahoo N, Kuotsu K. Nonionic surfactant vesicles in ocular delivery: innovative approaches and perspectives. BioMed Res Int. 2014 Jan 1;2014:263604. doi: 10.1155/2014/263604, PMID 24995280.
Ibrahim SS. The role of surface active agents in ophthalmic drug delivery: a comprehensive review. J Pharm Sci. 2019 Jun 1;108(6):1923-33. doi: 10.1016/j.xphs.2019.01.016, PMID 30684539.
Aboali FA, Habib DA, Elbediawy HM, Farid RM. Curcumin-loaded proniosomal gel as a bio friendly alternative for treatment of ocular inflammation: in vitro and in vivo assessment. Int J Pharm. 2020 Nov 15;589(3):119835.
Emad Eldeeb A, Salah S, Ghorab M. Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in vitro characterization, and in vivo pharmacodynamic study. Drug Deliv. 2019 Jan 1;26(1):509-21. doi: 10.1080/10717544.2019.1609622, PMID 31090464.
Fouda NH, Abdelrehim RT, Hegazy DA, Habib BA. Sustained ocular delivery of Dorzolamide-HCl via proniosomal gel formulation: in vitro characterization, statistical optimization, and in vivo pharmacodynamic evaluation in rabbits. Drug Deliv. 2018 Jan 1;25(1):1340-9. doi: 10.1080/10717544.2018.1477861, PMID 29869516.
Abreu CR. On the relationship between the hydrophilic-lipophilic balance and the nano architecture of nonionic surfactant systems. J Surfactants Deterg. 2019 Jan;22(5):1001-10.
Sayed S, Abdelmotelab M, Amin MM, Khowessah OM. Effect of formulation variables and gamma sterilization on trans corneal permeation and stability of proniosomal gels as ocular platforms for antiglaucomal drug. AAPS PharmSciTech. 2020 Apr;21(3):1-3.
Somjid S, Krongsuk S, Johns JR. Cholesterol concentration effect on the bilayer properties and phase formation of niosome bilayers: a molecular dynamics simulation study. J Mol Liq. 2018 Apr 15;256:591-8. doi: 10.1016/j.molliq.2018.02.077.
Moghassemi S, Hadjizadeh A. Nano-niosomes as nanoscale drug delivery systems: an illustrated review. J Control Release. 2014 Jul 10;185:22-36. doi: 10.1016/j.jconrel.2014.04.015, PMID 24747765.
Uchegbu IF, Florence AT. Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv Colloid Interface Sci. 1995 Jun 27;58(1):1-55. doi: 10.1016/0001-8686(95)00242-I.
Hsieh CJ, Chen YW, Hwang DW. Effects of cholesterol on membrane molecular dynamics studied by fast field cycling NMR relaxometry. Phys Chem Chem Phys. 2013;15(39):16634-40. doi: 10.1039/c3cp51739j, PMID 23965762.
Akhilesh D, Faishal G, Kamath JV. Comparative study of carriers used in proniosomes. Int J Pharm Chem Sci. 2012;3:6-12.
Verma S, Singh B, Katare OP. Proniosomal gel based delivery system of aceclofenac for ocular delivery with improved safety and efficacy. Acute Med Research. 2018;1(1):1-7.
Dhangar R, Bhowmick M, Parihar SS, Upmanyu N, Dubey B. Design and evaluation of proniosomes as drug carrier for ocular delivery of levofloxacin. J Drug Deliv Ther. 2014 Sep 14;4(5):182-9.
Keay LJ, Gower Ew, lovieno A, Oechsler RA, AlfonsobEc, Matoba A, Cavanagh D, Lee SM, Irvine J, Stulting RD, Mauger TF, Schein OD. Clinical and microbiological characteristics of fungal keratitis in the United States, 2001-2007: a multicenter study. Ophthalmology. 2011 May;118(5):920-6.
Satpathy G, Ahmed NH, Nayak N, Tandon R, Sharma N, Agarwal T. Spectrum of mycotic keratitis in north India: sixteen years study from a tertiary care ophthalmic centre. J Infect Public Health. 2019 May-Jun;12(3):367-71. doi: 10.1016/j.jiph.2018.12.005, PMID 30600158.
Published
How to Cite
Issue
Section
Copyright (c) 2023 AKHILESH PATEL, UJWAL HAVELIKAR, VIPIN SHARMA, SUCHITRA YADAV, SAKSHI RATHEE, BINITA GHOSH, KARTIK GILL, GAMDHUR SINGH, LALIT SHARMA, ARINDAM KOLAYARINDAM KOLAY
This work is licensed under a Creative Commons Attribution 4.0 International License.
